Travere Therapeutics (TVTX)
(Delayed Data from NSDQ)
$9.49 USD
+0.77 (8.83%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $9.49 0.00 (0.00%) 6:28 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Earnings News For TVTX
-
Travere: Q1 Earnings Snapshot
-
Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates
-
Travere Therapeutics Reports First Quarter 2024 Financial Results
-
Travere: Q4 Earnings Snapshot
-
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
-
Travere: Q3 Earnings Snapshot
-
Travere Therapeutics Reports Third Quarter 2023 Financial Results
-
Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for
-
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
-
Travere Therapeutics Reports Second Quarter 2023 Financial Results
-
Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates
-
Travere: Q1 Earnings Snapshot
-
Travere Therapeutics Reports First Quarter 2023 Financial Results
-
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Travere: Q4 Earnings Snapshot
-
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates
-
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
-
Analysts Estimate Travere Therapeutics (TVTX) to Report a Decline in Earnings: What to Look Out for
-
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
-
Travere: Q3 Earnings Snapshot
-
Travere Therapeutics Reports Third Quarter 2022 Financial Results
-
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
-
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
-
Travere: Q2 Earnings Snapshot
-
Travere Therapeutics Reports Second Quarter 2022 Financial Results